Department of Economics and Management, Kemerovo State University, 650000 Kemerovo, Russia.
Department of Management, Entrepreneurship and Engineering, Ural State University of Economics, 620144 Ekaterinburg, Russia.
Molecules. 2022 Jul 27;27(15):4812. doi: 10.3390/molecules27154812.
The current paper deals with the development of a new biologically active food supplement (BAFS) aimed at treating atherosclerosis. Since atherosclerosis is considered to be a disease of aging, the composition of the supplement includes such essential minerals as magnesium and potassium, which are commonly used to prevent atherosclerosis, as well as vitamins C, E and the B-group vitamins in order to address the needs of the elderly. The authors outline the supplement-manufacturing technology and discuss the clinical trial undertaken by patients, aged about 60 years, with peripheral atherosclerosis. The research methodology focuses on studying the effectiveness of the developed supplement by assessing the influence of the active ingredients on treating metabolic disorders. To establish the efficacy of the supplement, blood tests, ultrasound and physical examinations were applied. The combination therapy resulted in improved metabolism and an overall better performance of the cardiovascular system; therefore, the BASF can be recommended as part of combination therapy to prevent and treat atherosclerotic and age-related changes in blood vessels.
本文旨在开发一种新型的具有生物活性的食品补充剂(BAFS),以治疗动脉粥样硬化。由于动脉粥样硬化被认为是一种衰老疾病,该补充剂的成分包括镁和钾等必需矿物质,这些矿物质通常用于预防动脉粥样硬化,以及维生素 C、E 和 B 族维生素,以满足老年人的需求。作者概述了补充剂的制造技术,并讨论了对患有周围动脉粥样硬化的约 60 岁患者进行的临床试验。该研究方法侧重于通过评估活性成分对治疗代谢紊乱的影响来研究开发的补充剂的有效性。为了确定补充剂的功效,进行了血液检查、超声检查和身体检查。联合治疗改善了新陈代谢,心血管系统的整体功能也得到了改善;因此,该 BASF 可推荐作为预防和治疗血管粥样硬化和与年龄相关变化的联合治疗的一部分。